Magazine Article | May 2, 2022

Is Biopharma Poised For Bigger Deals In 2022?

Source: Life Science Leader

By Benet O'Reilly

After total deal value in the biopharma industry dipped to $108 billion in 2021 — its second-lowest level in eight years — it's natural to speculate whether that trend will continue in 2022. Will we see a resumption of transformative dealmaking? Or will we continue to see a high level of lower-value deals featuring bolt-on transactions, partnerships, and alliances?

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: